Comparison · NCT01428453-sae
Rilapladib 250mg Once Daily vs Placebo Once Daily: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Rilapladib 250mg Once Daily vs Placebo Once Daily: serious adverse events. Trial comparisons, record NCT01428453-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01428453-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.131 | 0.068 | 0.238 | wilson | |
| Risk in group 2 | 0.0806 | 0.0349 | 0.175 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0505 | -0.0633 | 0.167 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.63 | 0.563 | 4.69 | log | |
| Odds ratio, group 1 over group 2 | 1.72 | 0.53 | 5.59 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Rilapladib 250mg Once Daily than on Placebo Once Daily | 19.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Rilapladib 250mg Once Daily | Participants randomized to receive oral rilapladib 250 mg tablet once daily following breakfast for a period of 24 weeks. In addition to their stable background therapy consisting of an AChEI and/or memantine. | 8 | 61 | EG001 |
| Group 2 | Placebo Once Daily | Participants randomized to receive oral placebo tablet once daily following breakfast for a period of 24 weeks. In addition to their stable background therapy consisting of an AChEI and/or memantine. | 5 | 62 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Serious Adverse Event (SAE) and non-SAE were reported for treatment period only (up to Week 24).
Source ClinicalTrials.gov
Trial
- Title
- A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease
- NCT number
- NCT01428453
- Phases
- PHASE2
- Conditions
- Alzheimer's Disease
- Interventions
- 250mg rilapladib, placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2018-09-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01428453?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01428453-sae